Pomalidomide-C2-COOH

Background Introduction

Pomalidomide-C2-COOH is a specialized E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) research and related chemical biology applications. Incorporating pomalidomide—a small molecule recognized for recruiting the CRBN (cereblon) E3 ubiquitin ligase—this product features a two-carbon (C2) alkyl linker ending with a carboxylic acid (COOH) group, facilitating further functionalization and conjugation. This molecular platform enables scientists to efficiently design and synthesize novel PROTACs for targeted protein degradation strategies.

Mechanism

Pomalidomide-C2-COOH leverages the E3 ligase-binding capabilities of pomalidomide, which selectively engages with the cereblon (CRBN) complex, a component of the Cullin 4-RING E3 ubiquitin ligase. The C2 alkyl linker and terminal carboxylic acid provide a versatile and accessible handle for covalent attachment to ligands specific for proteins of interest. Once incorporated into a bifunctional PROTAC molecule, Pomalidomide-C2-COOH brings the target protein and the E3 ligase into close proximity, causing ubiquitination of the target and its subsequent degradation via the proteasome system. This process enables selective post-translational knockdown of disease-associated proteins at the cellular level.

Applications

Pomalidomide-C2-COOH is an indispensable building block for the custom synthesis of cereblon-recruiting PROTAC molecules. Its key applications include: (1) Facilitating the design and generation of PROTACs for targeted degradation of a wide range of proteins, including kinases, transcription factors, and epigenetic regulators; (2) Enabling functional studies of protein homeostasis and ubiquitin-proteasome pathway dynamics; (3) Supporting drug discovery workflows focused on novel therapeutics for cancer, neurodegenerative disorders, and other diseases linked to aberrant protein expression. Researchers can also utilize Pomalidomide-C2-COOH in the development of molecular glue degraders or in advanced chemical biology experiments requiring selective CRBN engagement.

Pomalidomide-C2-COOH is an E3 Ligase Ligand-Linker Conjugate that plays a crucial role in PROTACs by facilitating targeted protein degradation. It combines the selective binding of pomalidomide with a versatile linker, enabling efficient recruitment of E3 ligases to degrade disease-related proteins. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-C2-COOH is a two-carbon alkyl chain that provides moderate flexibility, allowing for optimal spatial arrangement between the ligand and the target protein. This linker is non-cleavable, ensuring stability and prolonged interaction with the target protein.

Ligand: The ligand component is based on pomalidomide, a thalidomide analog known for its high affinity to the cereblon E3 ligase. Its structural characteristics include a glutarimide ring, which facilitates selective binding to the E3 ligase, enhancing the efficacy of the PROTAC.

Reactive Site: The reactive site of Pomalidomide-C2-COOH features a carboxylic acid group, which is ideal for coupling with target protein ligands through amide bond formation. This site is compatible with carbodiimide-mediated coupling reactions, providing a reliable method for conjugation.

Recommended Target Protein Ligand: The recommended warhead for this molecule is an amine-containing ligand, which offers the advantage of forming stable amide bonds with the carboxylic acid group of Pomalidomide-C2-COOH. This compatibility ensures efficient formation of the PROTAC complex, facilitating the degradation of target proteins in cellular studies and advancing research in targeted protein degradation.